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a b s t r a c t
Cervical cancer is the fourth most common cancer in women, and seventh overall. This
disease represents a medical, economic and social burden. In early FIGO stage patients (IA,
IB1 and IIA1), nodal involvement is the most important prognostic factor. Imaging evaluation
of nodal metastasis is of limited value. In order to determine lymph node involvement, allow
loco-regional control of the disease, define the need for adjuvant radiotherapy and improve
survival, standard surgery for early disease is radical hysterectomy with systematic pelvic
lymphadenectomy. However, this surgical treatment has risks and complications: longer
operative time, larger blood loss, neurovascular or ureteral injury, lower-limb lymphedema,
symptomatic lymphocysts, hydronephrosis. A method that allows to define the presence
of regional metastasis with less morbidity and equal or greater precision is particularly
relevant. The use of the sentinel lymph node biopsy is intended to reach that purpose. The
present study reviews recent literature on the role of sentinel lymph node biopsy in cervical
cancer, analyzing its indications and contraindications, injection and detection techniques,
tracers used, surgical and pathological approaches and its applicability in up-to-date clinical
practice.
© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
1. Background
Cervical cancer is the fourth most common cancer in women,
and seventh overall, with an estimate of 528,000 new cases in
2012 worldwide. A large majority occurs in the less developed
regions (around 85% of them), where it accounts for almost
12% of all female cancers. There were an estimated 266,000
deaths from cervical cancer worldwide in 2012, accounting
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for 7.5% of all female cancer deaths. In Europe, its incidence
shows wide differences, with very low rates in countries like
Finland (5/100,000) and much higher rates in Czech Republic
(18/100,000) or Romania (30/100,000). This disease represents
a medical, economic and social burden considering that 65%
of the cases are diagnosed in women younger than 45 years of
age.1
https://doi.org/10.1016/j.rpor.2018.04.004
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Cervical cancer staging is based on the size of the primary
tumor and anatomical structures affected.2 However, treat-
ment election is based not only on the stage, but also on tumor
parameters (histological type and grade, tumor size, surgical
margins, depth of invasion, lymphovascular space invasion)
and the presence of lymph node involvement. In early stage
patients, nodal involvement is the most important prognos-
tic factor.3 In fact, 5-year survival decreases from 88–92% to
55–64% in cases of positive pelvic nodes, despite Federation
Internationale de Gynecologie et d’Obstetrique (FIGO) stage.4
Their number, location and size determine the prognosis and
treatment of the primary tumor and the affected territories
with chemo-radiotherapy. Nonetheless, latest FIGO staging
from 2009 does not include lymph node status.
Following FIGO staging, we can define early cervical cancer
as a tumor limited to the cervix, smaller than 4 cm (stages
IA, IB1 and IIA1), without parametrial involvement and no
suspicious images of regional disease.2 In the presence of
histological diagnosis, staging is done through clinical exam-
ination and might be complemented by cone biopsy and
radiodiagnostics techniques.5 When this group of patients
present negative nodes, high survival rates is the rule and
when they relapse, 66% of the cases do it in the pelvis. In
contrast, when positive nodes are found their survival is
significantly lower, and their relapses are only 55% in the
pelvis.6
Imaging evaluation of nodal metastasis is of limited value.
The sensitivity of computed tomography (CT) scan and mag-
netic resonance imaging (MRI) are low for metastatic lymph
node disease in patients with cervical cancer: 43% and 60%,
respectively.7 In patients with early stage cervical cancer,
the sensitivity of positron emission tomography (PET)/CT to
nodal involvement is also low (32–58%), although the speci-
ficity is high 93–97%.8 Therefore, preoperative evaluation
of nodal status with imaging techniques is not sensitive
enough to replace the histological examination of dissected
nodes.9
In order to determine lymph node involvement, allow
loco-regional control of the disease, define the need for adju-
vant radiotherapy and improve survival, standard surgery
for early disease is radical hysterectomy with systematic
pelvic lymphadenectomy. The approach could be either open,
laparoscopic or robot-assisted laparoscopic.5 However, this
surgical treatment has risks and complications. Patients
who undergo radical surgery and lymphadenectomy may be
exposed to longer operative time, larger blood loss, neu-
rovascular or ureteral injury and also suffer a significant
amount of complications in the long term: lower-limb lym-
phedema (10–15%), symptomatic postoperative lymphocysts
(12–34%), hydronephrosis (4%) and dysuria (20%).9–12 Patients
with early cervical cancer can present up to 27% positive
nodes.13 Therefore, most of them have historically undergone
unnecessary lymphadenectomies.9 Consequently, a method
that allows to define the presence of regional metastasis with
less morbidity and equal or greater precision is particularly
relevant. The use of the sentinel lymph node (SLN) biopsy
is intended to reach that purpose. The present study is a
review of recent literature on the role of SLN biopsy in cervical
cancer.
2. Definition and indications
The SLN is defined as the first node that drains a solid tumor;
its status is considered to be representative of the local and
regional lymph nodes status. The objective of SLN technique
is to perform a selective biopsy while preserving the remain-
ing lymph nodes in a way to limit morbidities, mostly those
related to the lymphatic system.14 This procedure was first
described by Cabanas forty years ago in patients with penile
carcinoma.15 Gradually, it has become the standard of care for
the management of melanoma, breast cancer and vulvar can-
cer, among other malignant lesions. The first experiences in
cervical cancer were published at the beginning of the 2000s
by O’Boyle et al. and Dargent et al.16,17; its feasibility has been
broadly studied thereafter.
A trained multidisciplinary team, with a completed learn-
ing curve, should be involved in the realization of this
technique.18 Even though the need for a learning curve has
been enunciated since its development, the minimum num-
ber of cases required to validate SLN biopsy has not been
determined yet. The tolerable margin for false-negative cases
also remains irresolute.19 Khoury-Collado et al. established
that 30 cases per surgeon are needed before achieving a good
detection rate. Detection rate was defined as the percentage of
procedures in which at least one sentinel node is identifiable.20
Current indications for SLN biopsy in cervical cancer com-
prise patients with early cervical cancer (FIGO stages: IA1
with lymphovascular space invasion, IA2, IB1 IIA1), with
squamous or adenocarcinomatous histology, without suspi-
cious images in the study of lymph node metastasis. The
contraindications are suspected extrauterine involvement,
presence of pathological pelvic or para-aortic lymph nodes
on radiological examination, previous history of surgery or
radiotherapy to nodal areas under study and contraindication
for surgical treatment (related to age or associated medi-
cal conditions). Pregnancy is not a formal contraindication
for SLN biopsy, even though the treatment choice for preg-
nant women with cervical cancer is based on FIGO stage
and gestational age at diagnosis.21,22 In nursing mothers,
breast-feeding should be suspended for 24 h after radiophar-
maceutical administration.19 Kadkhodayan et al. carried out
a systematic review and meta-analysis on SLN biopsy in cer-
vical cancer and showed that, even though tracer injection in
patients with previous conization might be technically chal-
lenging, they present a pooled detection rate of 91% and
therefore does not represent a contraindication. Nevertheless,
a history of neoadjuvant treatment (chemotherapy and/or
radiotherapy), usually limited to tumors larger than 2–3 cm or
to locally advanced disease,23,24 challenge the rate detection
and accuracy of SLN biopsy, limiting the utility of this tech-
nique in such scenarios. Still, larger studies in this subject are
needed.25
3. Tracers, injection technique and
detection rate
The procedures for SLN detection and localization involve
the injection of a blue dye usually combined with a
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radiopharmaceutical and/or a fluorescent agent. Subse-
quently, preoperative and/or intraoperative imaging can be
performed. Finally, intraoperative naked eye, gamma probe
or near-infrared (NIR) fluorescence imaging localization fol-
lowed by surgical removal of the detected lymph nodes are
performed.19
3.1. Blue dye
Initial studies of lymphatic mapping in patients with cervi-
cal cancer used only blue dye. Nonetheless, the detection rate
ranged from 70% to 100%.17 For this practice a water based
dye such as isosulfan blue, methylene blue, or patent blue is
injected into the cervix immediately after induction of anes-
thesia. These dyes bind weakly to plasma proteins; they are
largely excreted through the biliary tract. Intraoperatively, the
dye can be observed with the naked eye in both laparotomic
or minimally invasive approaches.3
Several injection techniques have been described, most of
them consisting in either cervical, tumoral or peritumoral.
Superficial and deep injections at the 3 and 9 o’clock posi-
tions or submucosal injection into each quadrant of the cervix
are the procedures most widely performed currently.3,17 All of
them present common effects related to the use of blue dye:
transient discoloration of the skin and urine and a decrease
in pulse oximetry readings due to colorimetric interference.26
Rarely, more severe reactions, such as anaphylaxis, may occur
(0.6%).27,28 Usually blue dyes spread rapidly and arrive SLN
about 5–10 min after injection. Further ahead, these sub-
stances might arrive at secondary non-SLN. Consequently, it is
relevant to perform SLN biopsy at the beginning of the surgical
procedure.3
3.2. Radioisotopes
The interstitial injection of radioactive tracers has been
widely spread in cervical cancer practice as well as in
many other tumors. 99mTechnetium-sulfur colloid is the sub-
stance most commonly used in the United States, whereas
99mTechnetium-nanocolloid serum albumin is mostly used
in Europe.12 The European Association of Nuclear Medicine
(EANM) guidelines describe that radiopharmaceutical injec-
tion should be peritumoral or periorificial into the four
quadrants of the cervix via a 20 or 22-gauge spinal needle.
Usual techniques are similar to those enounced for blue dyes.
In the case of previous conization, pericicatricial injection is
preferred, if feasible. Instillation should be superficial (sub-
mucosal) in small tumors. In bigger tumors, injection into
the necrotic part of the tumor should be carefully avoided.19
Important adverse reactions to radiocolloids have not been
described thus far.
At least three protocols have been described regarding tim-
ing and doses for 99mTc administration. Long protocols consist
of cervical injection of the tracer 20–24 h before the surgery.
Usual doses are high (2–4 mCi, 74–148 MBq) because half-life
of isotope is roughly 6 h; some institutions even repeat instil-
lation on the day of the surgery. In short protocols radiocolloid
is injected 2–4 h before surgery. Usual doses are between 0.2
and 1 mCi (7.4–37 MBq). Finally, ultra-short protocols comprise
injection of 0.4–0.55 mCi (14.8–20 MBq) in the operating room,
after induction of anesthesia (in combination with blue dye or
not). In this last case preoperative images are not performed.29
Following the injection of the tracer, lymphoscintigraphy
imaging is usually performed and it starts after 20–30 min in
order to show the progression of lymphatic flow and local-
ize SLNs. Most medical centers obtain images at 30 (early)
and 60–120 min (delayed) after injection. In order to acquire
planar and/or tomographic images (single photon emission
computed tomography – SPECT), a gamma camera with a
low-energy high-resolution collimator and single or multiple
heads and a large field of view is essential.12 More recently a
hybrid system with SPECT gamma camera and integrated CT
scanner (SPECT/CT) that fuses tomographic lymphoscintigra-
phy with anatomical data has been developed. It consists of
a dual-head variable-angle gamma camera armed with low-
energy high-resolution collimators and a low-intensity CT
scanner, delivering a 3D image with improved spatial resolu-
tion as compared to planar imaging. This allows for the precise
localization of the SLN within an anatomical background.19
When SLNs are located close to the cervix it is usually difficult
to detect them since the gamma-probe picks up high activity
from the injection site, which usually happens with parame-
trial nodes. SPECT/CT images are advantageous to distinguish
these SLNs, as well as contiguous SLNs and SLNs in infrequent
locations (para-aortic, presacral).30
Intraoperatively, a gamma-probe is used to acquire the
radioactive signal. The probe is handled slowly and carefully
in order to recognize even small SLNs in which the radiocol-
loid is retained.12 Lymph nodes with high gamma activity are
called hot nodes. They are identified in comparison with back-
ground radioactivity (average count rates of the surrounding
non-sentinel nodes and lymph node basin). The ratio of SLN
counts to background counts depend not only on the relapsed
time between tracer injection and surgery but also on the dose,
type of tracer injected and type of gamma probe used. These
ratios vary between 10:1 and 25:1. Supplementary SLN should
have a counting rate of at least 20% of the counting rate in
the hottest node detected. Nevertheless, residual radioactiv-
ity after exeresis must be lower than 10% of the counting rate
in the hottest node.31
3.3. Fluorescent agents
During last years, a third option that avoids radiation expo-
sure to patients has been raised: indocyanine green (ICG). It is
a fluorescent dye classically used in ophthalmology and car-
diology; it relies on NIR imaging. This dye presents high tissue
penetration and low autofluorescence, not being visible to the
human eye. It fluoresces in the NIR spectroscopy and this can
be detected intraoperatively using a fluorescence camera. A
recent meta-analysis by Ruscito et al.32 demonstrated that ICG
seems to be equivalent to the combination of blue dyes and
99mTc within terms of overall and bilateral detection rates in
cervical and endometrial malignancies. In a series of 227 cases
collected by three US institutions, Jewel et al. communicated
an overall detection rate of 95% and bilateral detection of 79%
using ICG.33 No significant adverse events have been reported
with ICG, except from rare anaphylactic reactions during its
ophthalmic or cardiologic use.3
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However, some authors point out that the use of ICG
does not provide guidance toward unexpected areas because
of the absence of preoperative images.34 In order to com-
bine a radio-guided and a fluorescence-guided approach, a
mix tracer which consists of both 99mTc-nanocolloid and ICG
has been industrialized (ICG-99mTc-nanocolloid). Neverthe-
less, Buda et al. recently published data obtained from 5
European institutions (144 patients) showing that detection
rate for ICG only cases was 100% whereas for 99mTc com-
bined with blue dye was 96%. Moreover, bilateral mapping was
accomplished in 98.5% for ICG and 76.3% for 99mTc with blue
dye (p < 0.0001).35 They also showed that even though there
was no significant difference between the two groups in terms
of bilateral mapping in patients with a tumor diameter less
than 2 cm, in the case of bigger tumors ICG showed a higher
bilateral mapping rate (100 vs. 64%; p = 0.001). This evidences
the possibility of avoiding the use of a radioactive agent such
as 99mTc.
3.4. Combined technique
When blue dye and radioisotope are combined to map lymph
nodes in patients with early cervical cancer, detection rates
seem to be improved over those with one method alone. In
their study of 211 women, Roy et al. found that the combined
method of lymphatic mapping has a detection rate of 99.1%,
compared to 92.8% rate with blue dye alone.36 The French SEN-
TICOL (Ganglion Sentinelle dans le Cancer du Col) prospective
trial, in which a combined technique was used in 133 out of
139 cases included, at least one SLN was detected in 97.8%
of patients whereas bilateral detection was accomplished in
76.5% of them.18
Many studies have pointed out that tumor size is relevant
for SLN detection. Rob et al. presented an analysis of stud-
ies published on SLN biopsy in early stage cervical cancer,
reporting a detection rate of 95% for tumors smaller than 2 cm,
whereas for bigger tumors, the same parameter dropped to
80%.29 In a more recent literature review, Tax et al. revealed
that blue dye and 99mTc combined technique shows a bilat-
eral detection rate of 87% and 83% in patients with a tumor
diameter of <2 cm and <4 cm, respectively.28
It is important to bear in mind that the resources and equip-
ment required for 99mTc mapping are not accessible to all
surgeons. It is costly and time consuming and demands a
nuclear medicine unit with safety protocols for handling.12
Blue dye is much cheaper and generally available in most
hospitals. Finally, the use of ICG is also expensive because
it requires the use of specialized equipment such as fluores-
cence camera.37
4. SLN mapping. Expected and unexpected
drainage routes
Based on the fact that the uterine cervix is a midline structure,
several drainage routes have been described. Considering that
the reasons for this distribution pattern (anatomic variations,
tumor size or location, tracer used, site of injection, etc.) have
not been clarified yet, the current consensus is that complete
lymph node dissection must be performed on the side/s where
no SLN is detected.38
Marnitz et al. claimed that exact and reproducible localiza-
tion of the pelvic lymph nodes is difficult due to the absence
of a uniform nomenclature for lymph nodes draining. They
proposed a mapping scheme of SLNs according to their usual
surgical procedure.39 Lymph nodes were labeled as para-aortic
lymph nodes/area 1 (all precaval and preaortic lymph nodes up
to the level of the aortic bifurcation), common iliac/area 2 (lymph
nodes between the bifurcation level of the aorta and the bifur-
cation of the iliac vessels), external iliac/area 3 (nodes situated
along the external iliac vessels, including the lymph nodes
in the lumbo-sacral fossa lateral to the iliac vessels), interil-
iac/area 4 (lymph nodes medial to the external iliac vessels,
those along the external iliac vein, lymph nodes of the obtu-
rator fossa and those covering the bifurcation of the common
iliac artery), internal iliac/area 5 (nodes medial to the internal
iliac vessel down to the level of the bifurcation of the uter-
ine vessels, including the presacral lymph nodes) and finally
parametric/area 6 (nodes situated at the bifurcation of the uter-
ine vessels) as it is shown in Fig. 1. According to Marnitz’s
retrospective analysis of the distribution pattern for sentinel
lymph nodes in 151 patients, they detected 406 sentinel lymph
nodes using either a single or a combined labeling technique
with 99mTc and/or blue dye: 17 were para-aortic (4%, area 1),
20 common iliac (5%, area 2), 20 external iliac (5%, area 3),
288 interiliac (71%, area 4), 33 internal iliac (8%, area 5) and 29
parametric (7%, area 6). When this group used the technique
of combined 99mTc and patent blue labeling, more nodes were
detected in the para-aortic area (7%, p = 0.006). The described
Fig. 1 – Cartographed localization of SLN by Marnitz et al.37
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distribution implies that SLN exploration should be started
at the interiliac/external iliac area (which account for more
than 75% of all SLNs detected) but must also include the
parametrial, presacral, iliac internal, common iliac und para-
aortic areas because these are the localizations for up to 8%
of SLNs. It may be observed that the prevalence of SLNs in
the parametrial area can range from 0% to 15%, and might
constitute the first and only site of metastasis. Nevertheless,
the concentration of technetium in the cervix does not per-
mit an accurate identification of these nodes, confirming the
importance of blue dye for this area. Patients with adeno-
carcinoma did not differ in their topographic distribution of
sentinel lymph nodes from those with squamous cell cervical
cancer.
Posteriorly Bats et al. validated Marnitz’s mapping scheme
but also pointed out that even though 80.6% of SLNs were
found in areas 4 and 5, 38.2% of patients had at least one SLN
in an unexpected area and 5.1% had SLNs only in unexpected
areas.40 Areas 1, 2, 5 and 6 were defined as unexpected. This
study included 139 patients with early cervical cancer. They
performed SLN detection with a combined labeling technique
followed by systematic pelvic lymphadenectomy as well as
lymphadenectomy of areas containing one or more SLNs. They
encountered SLN metastasis in 16.9% of patients with detected
SLNs. Thirteen percent of these metastasis were located only
in unexpected areas (para-aortic and parametrium) and they
were found only by SLN biopsy.
Concern has been raised regarding the possibility of
parametrial nodes (usually removed during radical hysterec-
tomy) being the first step in cervical cancer draining routes.
Both blue dye and radiocolloid are not usually highly effec-
tive to identify these nodes. Consequently, Frumovitz et al.
performed a study using a triple injection of blue dye,
99mTc and India ink. This third mapping agent stained
sentinel nodes black, allowing postoperative detection and
microscopic pathologic analysis in addition to usual preop-
erative and intraoperative identification. They included 20
patients: 25% of them showed no parametrial nodes identified
on histopathological final analysis. Five patients presented
metastatic disease to lymph nodes: 1 with metastasis in a
parametrial node and 4 patients in pelvic nodes. Of these
latter 4, one had disease that apparently skipped the ipsilat-
eral parametrial node, whereas the other 3 had no ipsilateral
parametrial lymph node identified on the side where the
pelvic node presented tumor cells. This data supports that
direct lymphatic drainage from the tumor to the pelvic nodes
exists and it can frequently bypass the parametrial nodes, if
they are present, ruling out the need for a technique that could
enhance these node’s detection rate.41
5. Surgical approach
Even though SLN biopsy can be performed via either open
surgery, laparoscopy or robot-assisted surgery, it has been
elicited that the two latter show a higher detection rate and
sensitivity.25 Moreover, fertility-sparing techniques (coniza-
tion and both simple and radical trachelectomy) are also
feasible in combination with SLN biopsy.42,43
Fig. 2 – Surgical algorithm for SLN biopsy by Cormier et al.36
(a) Intracervical injection; (b) including interiliac/subaortic
nodes; (c) exceptions made for select cases.
Adherence to SLN biopsy surgical algorithms is relevant
and allows to achieve a low false negative-rate. Fig. 2 shows
the algorithm proposed by Cormier et al.38 Direct visualiza-
tion of the pelvis allows the surgical team to identify blue
lymphatic channels and nodes. The following step consists
in the identification of the radioactive hot nodes with either
a hand-held/laparoscopic gamma-probe or fluorescent nodes
via NIR. After extirpation, it is recommended to perform an ex
vivo control outside the surgery field. Once SLNs are removed,
it is subsequently mandatory to corroborate the presence of
residual radioactivity/fluorescence emission in the pelvic and
para-aortic regions. As we previously mentioned, it is impor-
tant to look for parametrial SLNs based on direct visualization
of blue dye or ICG due to the high radioactive emission rates
near the cervix.
An essential aspect of SLN biopsy mapping is the detection
of at least one SLN for each pelvic side. If no SLN is found
in a hemipelvis, a side-specific lymphadenectomy must be
performed.35 In order to identify suspected, enlarged nodes,
a complete inspection should also be present during surgery.
Bulky, massively infiltrated lymph nodes can impair their
detection, regardless the tracer used. These nodes cannot be
identified as sentinel nodes (probably due to metastatic block-
age) and should not be eluded: they must be removed and sent
for intraoperative pathological analysis regardless of the SLN
mapping.16
If intraoperative pathological study shows a positive node,
proper treatment is based on chemo-radiation. Therefore,
hysterectomy might be omitted in order to avoid unneces-
sary morbidity without increasing overall survival,19 although
prospective randomized studies on the need of perform-
ing or abandoning radical hysterectomy are still required.44
The usefulness of undertaking a systematic para-aortic (with
or without pelvic) lymphadenectomy in order to tailor the
radiation field, following findings on locally advanced cervi-
cal cancer,45 remains controversial,19 although some authors
have elicited that this would not represent an added benefit
on overall survival.46
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6. Pathological analysis/ultrastaging
Characteristically frozen section has been used for the eval-
uation of SLNs. Nevertheless, several studies have found
that the precision of intraoperative frozen section evalua-
tion to detect micrometastasis, and small macrometastasis
is limited.3 Slama et al. described that overall sensitivity of
frozen section analysis was 56% for all types of metastasis,
mainly due to its inability to detect low volume disease.47 In
this series of 225 patients, frozen section was only able to
detect 2 out of 17 cases of micrometastasis and none of 8 cases
with isolated tumor cells (ITC).
Pathologic ultrastaging includes multiple serial sectioning
and immunohistochemical assessment of SLNs. It permits
the detection of low-volume metastasis of less than 2 mm,
including both micrometastasis (0.2–2 mm) and ITC (less
than 0.2 mm). In a large retrospective cohort study with 645
patients, macrometastasis (tumor deposits larger than 2 mm),
micrometastasis and ITC were detected by ultrastaging and
staging of all other pelvic lymph nodes in 21%, 7%, and 4%
of cases, respectively.48 The sensitivity of SLN ultrastaging
reached 91% in the entire group and 97% in patients with
bilateral SLN detection, with a false negative rate of 1.3%. This
allows to identify nodal involvements that would have never
been detected with standard techniques.
Furthermore, according to the analysis of the same cohort
made by Cibula et al., the overall survival of patients with
micrometastasis (7.1% of the sample) was similar to patients
with macrometastasis, and this was statistically significant
compared to patients with negative SLNs (p < 0.001).49 The
presence of micrometastasis was an independent prognostic
factor for survival. No prognostic significance was found for
ITC.
The one factor that was significantly more frequent in
a subgroup with false negative results was the presence of
lymphovascular space invasion (not age, histological type,
number of removed SLN nor tumor stage), but this constituted
a very small group to make a strong conclusion. Regardless
of the broad evidence regarding ultrastaging on SLN biopsy
in cervical cancer, it is still scarcely used in current clinical
management.49
7. Clinical relevance of SLN biopsy as an
alternative to lymphadenectomy
In order to weigh SLN biopsy trustworthiness, sensitivity and
false negative rate are crucial. They assess the possibility of
metastatic involvement of the rest of pelvic lymph nodes
when SLNs are negative. There is good evidence of the high
sensitivity of SLN biopsy concept in cervical cancer. To the
best of our knowledge, most of the evidence arises from ret-
rospective trials and one prospective trial.
Lécuru et al. published the formerly referred SENTI-
COL prospective multicenter study with 139 patients that
presented IA1 to IB1 cervical cancer. They applied SLN ultra-
staging, obtaining a sensitivity of 92% (95% CI, 74.0–99%) for
the whole group and 100% in patients with bilateral SLN
detection.18 Negative predictive value (NPV) was 98.2% (95% CI,
93.8–99.8%) for the whole sample. As previously mentioned,
Cibula et al. published the largest retrospective multicenter
study to the date and registered 645 stage IA1 to IIB patients,
also performing ultrastaging. They showed an overall sensi-
tivity of 91% and 97% for patients with bilateral detection.48
Sensitivity was not compromised in larger tumors or in higher
stages in patients with bilateral SLN detection.
Tax et al. performed a literature review that included 47
studies reporting results on SLN detection, in patients with
early stage cervical cancer, totaling 4130 cases. When consid-
ering only ultrastaging studies, they obtained a sensitivity of
94% and a NPV range of 91–100% (compared to a sensitivity of
68% and NPV range of 59–100% from frozen section and/or H&E
analysis). Ultrastaging showed 19 false negative cases out of
1275 patients, with a 1.5% consequent risk of undertreatment.
Nevertheless, the author explored the characteristics of these
19 patients, concluding that adding more specific criteria for
the selection of cases, 18 cases would have been prevented,
decreasing the chance of undertreatment to 0.08% (1/1257).
Such criteria were: (1) bilateral detection, (2) early FIGO stages
IA2, IB1, IIA, (3) no suspicious lymph nodes during either
pre-operative imaging or surgery and (4) primary tumor size
smaller than 40 mm. Overall, when the latter criteria were met,
estimated sensitivity was 99.6% (95% CI: 98–100%) and NPV
99.9%. In melanoma, breast and vulvar cancer, the remaining
risk of 3%, 0–10% and 2% of metastasis in non-SLN have been
considered adequate to abandon lymphadenectomy.28
SLN biopsy not only reduces surgical time, blood loss, rate
of infection, lymphocele and lymphedema but it can also
improve detection of lymph node metastasis compared to
lymphadenectomy.50 Aberrant lymphatic drainage pathways,
positive evidence of lymph node removal, and ultrastaging
enhance the power of this technique.11 Currently, a prospec-
tive observational trial on sentinel lymph node biopsy in
patients with early stage cervical cancer, the SENTIX (SENTinel
lymph node in cervIX cancer) trial (CEEGOG CX-01; ENGOT-Cx
2; NCT02494063) is in recruitment phase. It is the first prospec-
tive trial willing to evaluate whether SLN biopsy is non-inferior
to treatment with systematic pelvic lymphadenectomy.
8. Conclusion
Lymph node status remains a main factor for the progno-
sis and management of cervical cancer. The use of SLN
biopsy in clinical practice is justified by the lower number of
unnecessary lymph node dissections and its consequences
in terms of surgical time, complications and posterior mor-
bidity. Moreover, an additional benefit from SLN includes a
better information about nodal status (unusual drainage sites)
and a high rate of low-volume metastasis detection (ultrastag-
ing). Nowadays, SLN biopsy represents a cornerstone in the
management of early stage cervical cancer patients by multi-
disciplinary trained teams in validated centers.
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